Crystalline forms of an antiviral compound
Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
1. A crystalline form of compound I:
wherein, the crystalline form is
an ethanol solvate (Compound I Form I), characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 8.6, 11.1, and 15.5 °2θ as determined on a diffractometer using Cu-Kα radiation.
2. Compound I Form I according to claim 1 , wherein the diffractogram further comprises
a peak at 12.9 °2θ±0.2°.
3. A pharmaceutical composition comprising a Compound I Form I according to claim 1 , and a pharmaceutically acceptable excipient.
4. A method for treating a subject suffering from hepatitis C virus (HCV), comprising administering to the subject a therapeutically effective amount of a Compound I Form I according to claim 1 and a pharmaceutically acceptable excipient.
5. The method according to claim 4 , comprising further administering to the subject at least one anti-HCV agent.
6. Compound I Form I according to claim 1 , wherein the diffractogram is substantially as shown in FIG. 1 .
7. Compound I Form I according to claim 1 , characterized by a differential scanning calorimetry (DSC) curve substantially as shown in FIG. 2 .
8. Compound I Form I according to claim 1 , characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 149° C., an exotherm at about 212° C., and an endotherm at about 275° C.
9. Compound I Form I according to claim 1 , characterized by a thermogravimetric analysis (TGA) comprising a thermogram substantially as shown in FIG. 3 .
10. Compound I Form I according to claim 1 , characterized by a thermogravimetric analysis (TGA) with a weight loss of about 8.4% in a temperature range of about 30° C. to about 350° C.
11. Compound I Form I according to claim 1 , characterized by a dynamic vapor sorption (DVS) curve substantially as shown in FIG. 4 .
12. New Compound I Form I according to claim 1 , characterized by a nuclear magnetic resonance spectrum ( 1 H NMR) substantially as shown in FIG. 5 .
13. Compound I Form I according to claim 1 , further comprising about 1.7 mole equivalents of ethanol.